Novartis Social Business Careers: improving health in lower income countries

This is the story of how 3 Novartis colleagues took a career decision to improve health in lower income countries.

This series provides a glimpse into their experiences, challenges and the reward of seeing lives changed.

…
/by

International Women’s Day 2020

At Novartis, our people are exceptional. They do amazing work every day to reimagine medicine and improve the lives of patients all over the world. We want to build an inclusive environment that values these unique and curious minds, where everyone is inspired to innovate every day by this shared purpose to reimagine medicine.  

That’s why we’re committed to building an inclusive and equitable workplace that looks beyond gender and empowers all of our associates to follow their dreams 

Here are some of their stories:

Maryam is a cognitive robotics expert …

/by

International Women’s Day 2020

At Novartis, our people are exceptional. They do amazing work every day to reimagine medicine and improve the lives of patients all over the world. We want to build an inclusive environment that values these unique and curious minds, where everyone is inspired to innovate every day by this shared purpose to reimagine medicine.  

That’s why we’re committed to building an inclusive and equitable workplace that looks beyond gender and empowers all of our associates to follow their dreams 

Here are some of their stories:

Maryam is a cognitive robotics expert …

/by

Advancing medicine through collaboration

Wendi Yajnik has been building partnerships between academia and industry for the better part of her career. When it comes to emerging technologies, she’s seen it all – from cancer-fighting immunotherapies to gene editing tools to an approach to fat loss inspired by ice pops.

Now at Novartis, Yajnik heads Academic Partnerships and External Innovation for the Novartis Institutes for BioMedical Research (NIBR). Her team is responsible for bringing exciting new discoveries and technologies into Novartis from academia. Their efforts are helping drive NIBR’s strategy to build an …

/by

International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa

  • EDCTP grants the PAMAfrica research consortium €21.9 million over a 5 year period; MMV, Novartis and other partners will provide an additional €22 million.
     
  • The PAMAfrica consortium brings together a global medicines company, a not-for-profit product development partnership and leading academic institutions in Africa and Europe. PAMAfrica aims to develop new medicines for both severe and uncomplicated malaria, designed to combat emerging artemisinin resistance.
     
  • The projects will include development of the first new malaria …
/by

Sandoz Resolves Generic Drug Antitrust Investigation in the U.S.

Princeton, New Jersey, March 2, 2020 – Sandoz Inc. has reached a resolution with the U.S. Department of Justice (DOJ) Antitrust Division concerning the Department’s more than three-year-long antitrust investigation into the U.S. generic drug industry. The Sandoz resolution relates to instances of misconduct at the company between 2013 and 2015 with regard to certain generic drugs sold in the United States. As part of the resolution, Sandoz has agreed to pay USD 195 million and will enter into a deferred prosecution agreement (DPA).

Sandoz is a global leader in …

/by

Novartis provides update on use and safety of Beovu® in patients with wet AMD

March 11, 2020

Patient safety is at the heart of everything we do. Whenever adverse events are reported, we take them seriously and investigate them thoroughly. 

As previously shared, our global safety organization is conducting a comprehensive review of a limited number of events reported as severe vision loss, retinal artery occlusion and/or vasculitis in patients treated with Beovu, including cases where patients had previously received other VEGF inhibitors. 

To date, the data continue to support an overall favorable benefit-risk profile for …

/by

Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting

  • Shareholders approve 23rd consecutive dividend increase to CHF 2.95 (+4%) per share for 2019; representing a 3.5%1 yield and approximately 54% payout of free cash flow
     
  • Shareholders confirm Dr. Joerg Reinhardt as Chairman of the Board of Directors as well as all other members who stood for re-election; Ms. Bridgette Heller and Mr. Simon Moroney elected to the Board of Directors
     
  • Shareholders approve all other proposals of the Board of Directors, including the 2019 Compensation Report in an advisory …
/by

Parental Leave at Novartis: Alfred’s story

At Novartis, we celebrate life and recognize moments that matter. One of the most life-changing moments our associates experience is becoming a parent and welcoming new life into their lives. In July 2019, we introduced equal paid parental leave of at least 14 weeks to all parents, regardless of gender. We believe that this will empower our people to make the right choices for the health and well-being of their families, by enjoying more flexibility and financial stability, at the times when it matters the most.

…

/by

Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis

  • LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust
     
  • Novartis is responsible for completing Phase I clinical trials and has committed to maximizing access in endemic countries, once approved
     
  • DNDi will lead Phase II and III clinical development, starting in India with additional trials planned in East Africa
     
  • Leishmaniasis, which is transmitted by the sand fly, affects over one billion people; visceral leishmaniasis, the most serious form of the …
/by